资源描述：
《健脾益肾养肝方联合聚乙二醇干扰素治疗HBeAg阳性慢性乙肝的临床研究.doc》由会员上传分享，免费在线阅读，更多相关内容在工程资料-天天文库。
1、健脾益肾养肝方联合聚乙二醇干扰素治疗HBeAg阳性慢性乙肝的临床研究［摘要］研究健脾益肾养肝方联合聚乙二醇干扰素治疗HBeAg阳性慢性乙肝（HP-HBV）的临床疗效。选择2012年6月一2014年12月接受治疗的11PH1BV患者126例，给予聚乙二醇干扰素-a-2a（或a-2b）治疗24周，按照HBV-DNA水平分为应答组与应答不佳组，应答不佳组依据随机数字表法平均分为对照组与试验组，对照组继续单纯使用聚乙二醇干扰素-a-2a（或a-2b）治疗，试验组采用聚乙二醇干扰素-a~2a（或a-2b）联合健
2、脾益肾养肝方治疗。观察各组治疗前，治疗24周HBeAg,ALT及HBV-DNA水平变化；治疗48周病毒学应答、血清学应答及生化学应答，临床症状及体征积分，不良反应等指标。结果显示，治疗24周后，应答组HBeAg,ALT,HBV-DNA水平显著优于应答不佳组（P<0.05）□治疗48周，应答组、应答不佳组HBV-DNA阴转率、HBeAg阴转率存在统计学差异（P<0.05）o试验组HBV-DNA阴转率、HBeAg阴转率显著优于对照组（P<0.05）o试验组治疗48周临床症状及体征积分显著低于对照组（P<0
3、.05）,试验组不良反应发生率（0%）显著低于对照组（8.70%）（P〈0.05）o表明健脾益肾养肝方联合聚乙二醇干扰素治疗HP-HBV女全有效，值得应用于临床。［关键词］健脾益肾养肝方；聚乙二醇干扰素；HBeAg阳性慢性乙肝Abstract]Toobservetheclinicalefficacyofspleen,1iverandkidney-strengtheningformulacombinedwithpolyethyleneglycolinterferoninthetreatmentofHBe
4、AgpositivechronichepatitisB(HP-HBV).Onehundredandtwenty-sixpatientswithHP-HBV,whoweretreatedinthehospitalfromJune2012toDecember2014,wereselectedandinjectedwithpolyethyleneglycolinterferona-2a(ora-2b).Thetreatmentcourseforthepatientslastedfor24weeks.Base
5、onthelevelofHBV-DNA,patientsaredividedintoresponsegroupandpoorresponsegroup・Accordingtorandomnumbertable,thepoorresponsegroupwererandomizedintocontrolgroupandtestgroup・Patientsinthecontrolgroupwereinjectedwithpolyethyleneglycolinterferona~2a(orQ-2b),and
6、patientsinthetestgroupweretreatedwithspleen,liverandkidney-strengtheningformulacombinedwithpolyethyleneglycolinterferon.Clinicalefficaciesofthe2groupswereobserved,且ndchangesinthelevelofHBeAg,ALTandHBV-DNAwereobservedbeforetreatmentandatthe24thweekaftert
7、reatment,andvirologicalandserologicalresponse,biochemicalresponses,integralclinicalsymptomsandsigns,adversereactionswereobservedafter48weeksoftreatment.After24weeksoftreatment,theresponsegroupwassignificantlybetterthanthepoorresponsegroupinHBeAg,ALTandt
8、helevelofHBV-DNA(P<0.05)・After48weeksoftreatment,therewasstatisticalsignificanceinHBV-DNAnegativeconversionrate,UBeAgnegativeconversionratebetweenthe2groups(P<0.05),andthetestgroupwasbetterinthetwoindicators・Andthetestgroupwassig
